首页|期刊导航|肿瘤学与转化医学（英文）|Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies

Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies

Bili Wu Guangyuan Hu Xianglin Yuan Bo Liu Xueyan Jiang Ye Yuan Wan Qin Kai Qin Qi Mei Li Zhang Huilan Zhang

肿瘤学与转化医学（英文）2021，Vol.7Issue(3)：108-114,7.

肿瘤学与转化医学（英文）2021，Vol.7Issue(3)：108-114,7.DOI:10.1007/s10330-021-0488-8

Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies

Bili Wu ¹Guangyuan Hu ¹Xianglin Yuan ¹Bo Liu ¹Xueyan Jiang ¹Ye Yuan ²Wan Qin ¹Kai Qin ¹Qi Mei ¹Li Zhang ¹Huilan Zhang³

作者信息

1. Department of Oncology,Tongji Hospital,Tongji Medical College,University of Science and Technology,Wuhan 430030,China
2. Department of Gastroenterology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
3. Department of Respiratory and Critical Care Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
折叠

摘要

关键词

coronavirus disease (COVID-19)/cancer/immunoglobulin (Ig) G/IgM

Key words

coronavirus disease (COVID-19)/cancer/immunoglobulin (Ig) G/IgM

引用本文复制引用

Bili Wu,Guangyuan Hu,Xianglin Yuan,Bo Liu,Xueyan Jiang,Ye Yuan,Wan Qin,Kai Qin,Qi Mei,Li Zhang,Huilan Zhang..Seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer and the impact of anti-tumor treatment on antibodies[J].肿瘤学与转化医学（英文）,2021,7(3):108-114,7.

基金项目

Supported by the research grants from the National Natural Science Foundation of China(No.81773360,and No.81902619)and （No.81773360,and No.81902619）

肿瘤学与转化医学（英文）

OACSTPCD

ISSN：2095-9621

访问量0

下载量0

段落导航